These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30946085)

  • 81. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.
    Fang HY; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27878893
    [TBL] [Abstract][Full Text] [Related]  

  • 82. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.
    Appelt AL; Pløen J; Harling H; Jensen FS; Jensen LH; Jørgensen JC; Lindebjerg J; Rafaelsen SR; Jakobsen A
    Lancet Oncol; 2015 Aug; 16(8):919-27. PubMed ID: 26156652
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Does one size fit all? Risks and benefits of neoadjuvant chemoradiation in patients with clinical stage IIA rectal cancer requiring abdominoperineal resection.
    de Camargo MGM; Xhaja X; Aiello A; Liska D; Gorgun E; Dietz DW; Kalady MF; Delaney CP; Steele SR; Valente MA
    Am J Surg; 2020 Mar; 219(3):406-410. PubMed ID: 31672306
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.
    Probst CP; Becerra AZ; Aquina CT; Tejani MA; Wexner SD; Garcia-Aguilar J; Remzi FH; Dietz DW; Monson JR; Fleming FJ;
    J Am Coll Surg; 2015 Aug; 221(2):430-40. PubMed ID: 26206642
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Locally advanced rectal cancer: Preliminary results of rectal preservation after neoadjuvant chemoradiotherapy.
    Vaccaro CA; Yazyi FJ; Ojra Quintana G; Santino JP; Sardi ME; Beder D; Tognelli J; Bonadeo F; Lastiri JM; Rossi GL
    Cir Esp; 2016 May; 94(5):274-9. PubMed ID: 26980259
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis.
    Sung S; Kim SH; Lee JH; Nam TK; Jeong S; Jang HS; Song JH; Lee JW; Bae JM; Lee JH
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):647-653. PubMed ID: 28581407
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.
    Marinello FG; Frasson M; Baguena G; Flor-Lorente B; Cervantes A; Roselló S; Espí A; García-Granero E
    Dis Colon Rectum; 2015 Jun; 58(6):556-65. PubMed ID: 25944427
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
    Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
    BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation.
    Tawfik B; Mokdad AA; Patel PM; Li HC; Huerta S
    Anticancer Drugs; 2016 Oct; 27(9):879-83. PubMed ID: 27434664
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of clinical outcomes of conservative treatment and surgery for esophageal cancer patients who achieve a clinical complete response following neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
    Sun Z; Zheng J; Xu X; Zhao X; Ma X; Ye Q
    Ann Transl Med; 2022 Dec; 10(24):1378. PubMed ID: 36660656
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Outcome and Salvage Surgery Following "Watch and Wait" for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review.
    Kong JC; Guerra GR; Warrier SK; Ramsay RG; Heriot AG
    Dis Colon Rectum; 2017 Mar; 60(3):335-345. PubMed ID: 28177997
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Watch and wait approach in rectal cancer: Current controversies and future directions.
    López-Campos F; Martín-Martín M; Fornell-Pérez R; García-Pérez JC; Die-Trill J; Fuentes-Mateos R; López-Durán S; Domínguez-Rullán J; Ferreiro R; Riquelme-Oliveira A; Hervás-Morón A; Couñago F
    World J Gastroenterol; 2020 Aug; 26(29):4218-4239. PubMed ID: 32848330
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided?
    Ayloor Seshadri R; Kondaveeti SS; Jayanand SB; John A; Rajendranath R; Arumugam V; Raj Ellusamy H; Sagar TG
    Hepatogastroenterology; 2013 May; 60(123):410-4. PubMed ID: 23635444
    [TBL] [Abstract][Full Text] [Related]  

  • 96. MRI morphologic and clinicopathologic characteristics for predicting outcomes in patients with locally advanced rectal cancer.
    Meng Y; Wan L; Ye F; Zhang C; Zou S; Zhao X; Xu K; Zhang H; Zhou C
    Abdom Radiol (NY); 2019 Nov; 44(11):3652-3663. PubMed ID: 30456561
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patterns.
    Yamamoto T; Kawada K; Hida K; Ganeko R; Inamoto S; Yoshitomi M; Watanabe T; Sakai Y
    Int J Clin Oncol; 2019 Jun; 24(6):677-685. PubMed ID: 30721379
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Watch-and-wait strategy in rectal cancer: Is there a tumour size limit? Results from two pooled prospective studies.
    Jankowski M; Pietrzak L; Rupiński M; Michalski W; Hołdakowska A; Paciorek K; Rutkowski A; Olesiński T; Cencelewicz A; Szczepkowski M; Zegarski W; Reszke J; Richter P; Wawok P; Małecki K; Bębenek M; Szelachowska J; Mazurek M; Gisterek I; Polkowski W; Jankiewicz M; Styliński R; Socha J; Bujko K;
    Radiother Oncol; 2021 Jul; 160():229-235. PubMed ID: 34023328
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
    Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
    Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Neoadjuvant chemoradiation for rectal cancer is not associated with higher rates of thromboembolism.
    Smart PJ; Stocchi LL; Remzi FH
    Colorectal Dis; 2015 Nov; 17(11):984-9. PubMed ID: 25988216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.